Feds Probe Novartis AG Over Marketing of Its Gilenya MS Pill
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
Novartis marketing is under a microscope. The US Attorney in New York has issued a civil investigative demand to the drugmaker for documents and information concerning its marketing practices for the Gilenya multiple sclerosis treatment. And the feds want to know about the “renumeration of health care providers,” which is another way of asking about how much money or goodies were given to doctors. The move comes as Novartis faces a heated battle in the competitive multiple sclerosis market. A few months ago, Biogen began debuted its Tecfidera pill, which one analyst described at the time as the 'holy mother' of all drug launches, since the drug generated a sizeable number of prescriptions very quickly.
Help employers find you! Check out all the jobs and post your resume.
Novartis marketing is under a microscope. The US Attorney in New York has issued a civil investigative demand to the drugmaker for documents and information concerning its marketing practices for the Gilenya multiple sclerosis treatment. And the feds want to know about the “renumeration of health care providers,” which is another way of asking about how much money or goodies were given to doctors. The move comes as Novartis faces a heated battle in the competitive multiple sclerosis market. A few months ago, Biogen began debuted its Tecfidera pill, which one analyst described at the time as the 'holy mother' of all drug launches, since the drug generated a sizeable number of prescriptions very quickly.
Help employers find you! Check out all the jobs and post your resume.